Apex Healthcare Berhad Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017
February 21, 2018
Share
Apex Healthcare Berhad reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported revenue of MYR 152,585,000 compared to MYR 144,146,000 a year ago. Profit before tax was MYR 16,380,000 compared to MYR 10,079,000 a year ago. The increase is due mainly to the recognition of MYR 2.9 million as share of results from associate in the current quarter, attributed to higher sales and a greater proportion of high margin products in the associates' revenue mix. Net profit was MYR 12,799,000 compared to MYR 6,766,000 a year ago. Net profit attributable to owners of the parent was MYR 12,801,000 or 10.91 sen per diluted share compared to MYR 6,757,000 or 5.77 sen per diluted share a year ago.
For the year, the company reported revenue of MYR 620,264,000 compared to MYR 581,269,000 a year ago. Profit before tax was MYR 56,047,000 compared to MYR 46,294,000 a year ago. Net profit was MYR 44,488,000 compared to MYR 34,988,000 a year ago. Net profit attributable to owners of the parent was MYR 44,459,000 or 37.90 sen per diluted share compared to MYR 34,955,000 or 29.83 sen per diluted share a year ago. Net cash flows generated from operating activities were MYR 46,204,000 compared to MYR 33,796,000 a year ago. Purchase of property, plant and equipment & intangible assets was MYR 37,073,000 compared to MYR 10,651,000 a year ago.
Apex Healthcare Berhad is a Malaysia-based healthcare company. The Company is focused on the development, manufacturing, wholesaling, marketing and distribution of pharmaceuticals, consumer healthcare products, and medical devices. It operates through three segments: Manufacturing, Distribution and Corporate. It is engaged in the manufacturing of pharmaceutical products. It is involved in the distribution of pharmaceutical and healthcare products. The Corporate segment comprises investments, properties and others. It is also engaged in the contract manufacturing of orthopedic devices. Its brands include XEPATM, AVO, AGNESIA, AEVA and HENNSON, and products bearing these brands are sold in approximately 16 territories worldwide. The Company's distribution channels reach hospitals, clinics, independent and chain pharmacies, supermarkets and health stores, enabling products to reach customers, namely doctors, pharmacists, nutritionists, retailers, and ultimately the patients or consumers.
APEX HEALTHCARE 
